List of Excipients in Branded Drug ASTELIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	ASTELIN	azelastine hydrochloride	54868-5072	BENZALKONIUM CHLORIDE

Astelin Excipient Strategy and Commercial Opportunities for Azelastine Nasal Spray

Last updated: August 7, 2026

Astelin is a prescription azelastine hydrochloride nasal spray for seasonal allergic rhinitis. Its commercial position is based on a mature, low-complexity aqueous formulation, established clinical use, and broad generic availability rather than an active-composition patent moat. The strongest opportunities are preservative-free delivery, improved nasal tolerability, device differentiation, OTC conversion, combination therapy, and contract development of azelastine nasal products.

What is Astelin and how is it formulated?

Astelin contains azelastine hydrochloride at 0.1%, delivering 137 micrograms of azelastine hydrochloride per spray. The product is an aqueous nasal solution administered through a metered-dose pump. It is indicated for seasonal allergic rhinitis in adults and pediatric patients aged five years and older under the U.S. prescription label.[1]

The labeled inactive ingredients are:

Excipient	Likely formulation function
Benzalkonium chloride	Antimicrobial preservative
Edetate disodium	Chelating agent; supports preservative performance and chemical stability
Hypromellose	Viscosity modifier and mucosal residence aid
Sodium citrate	Buffering agent
Sodium chloride	Tonicity adjustment
Purified water	Vehicle

The labeled formulation has an approximate pH range of 6.5 to 8.0. The formulation is designed to balance solubility, chemical stability, spray performance, nasal comfort, and microbiological protection.[1]

What is the active pharmaceutical ingredient in Astelin?

The active ingredient is azelastine hydrochloride, a topical H1 antihistamine. Azelastine has antihistaminic, mast-cell-stabilizing, and anti-inflammatory activity. The nasal route provides local exposure with relatively limited systemic exposure compared with oral antihistamines.[1,2]

What dosage form and delivery system does Astelin use?

Astelin is a multidose nasal spray using a mechanical metering pump. The commercial system depends on:

• Consistent delivered volume per actuation
• Uniform droplet and plume characteristics
• Adequate priming and re-priming behavior
• Reliable dosing near the end of container life
• Compatibility between formulation, pump, dip tube, container, and closure
• Microbiological control after repeated patient use

For a mature nasal product, the device is as important as the excipient system. A formulation change that alters viscosity, surface tension, density, or pH can change spray pattern, plume geometry, and delivered dose.

What excipients protect Astelin stability and manufacturability?

Astelin uses a conventional excipient architecture rather than a highly specialized delivery platform.

Benzalkonium chloride

Benzalkonium chloride is the principal preservative. Multidose aqueous nasal products require protection against microbial contamination introduced during repeated use. Its concentration must be sufficient for preservative efficacy without causing unacceptable local irritation.

The commercial tradeoff is significant. Long-term or repeated exposure to benzalkonium chloride has been associated with concerns about nasal mucosal irritation and epithelial effects, particularly in patients using nasal products chronically.[3] That creates a formulation opportunity for preservative-free products or alternative preservation systems.

Edetate disodium

Edetate disodium binds trace metal ions that can catalyze degradation reactions. It can also improve preservative performance by weakening microbial cell-envelope defenses. The excipient is used at low levels and generally has limited impact on spray characteristics.

Hypromellose

Hypromellose increases viscosity and can improve retention on the nasal mucosa. It may reduce rapid runoff into the throat and support local residence time. Its concentration must remain low enough to preserve pumpability and acceptable spray atomization.

Excessive viscosity can create:

• Reduced pump reproducibility
• Larger or less uniform droplets
• Poor plume geometry
• Increased residual volume
• Greater sensation of nasal blockage

Hypromellose therefore represents a useful optimization variable, but not an unconstrained performance enhancer.

Sodium citrate and sodium chloride

Sodium citrate establishes buffering capacity and contributes to pH control. Sodium chloride adjusts osmolality and can improve nasal comfort. A formulation that is too acidic, too alkaline, or substantially hypotonic or hypertonic can increase burning, stinging, or run-off.

Purified water

Purified water is the continuous phase. Water quality, microbial control, container closure integrity, and manufacturing controls are central to product quality because the formulation is an aqueous multidose system.

What formulation patents protect Astelin?

Astelin's original active-ingredient and formulation exclusivity has expired. The U.S. market contains generic azelastine hydrochloride nasal spray products, and the product is no longer protected by a meaningful composition-of-matter patent barrier.

The key commercial protection has historically come from:

1. The original azelastine molecule and development program.
2. FDA approval of the nasal-spray dosage form.
3. Brand recognition and prescriber familiarity.
4. Device and manufacturing know-how.
5. Later product repositioning, including OTC azelastine products and combination therapy.

Public U.S. FDA Orange Book records should be used for a current product-specific patent check. The original Astelin NDA is generally identified as NDA 020114. No active, commercially decisive Orange Book patent barrier is known to prevent generic azelastine nasal-spray entry in the United States.[4]

Are Astelin's excipients patentable?

Individual excipients such as benzalkonium chloride, hypromellose, sodium citrate, sodium chloride, and edetate disodium are established pharmaceutical ingredients and are not proprietary to Astelin.

A company could seek patent protection for a narrower formulation or delivery system involving:

• A preservative-free azelastine solution
• A defined pH and osmolality window
• A specific viscosity profile
• An alternative antimicrobial system
• A low-irritation formulation
• A pump with specified plume and droplet characteristics
• A dose-counter or end-of-life indicator
• A unit-dose or multidose container
• A combination of azelastine with a corticosteroid
• A formulation with improved stability under temperature stress

Such claims would need to demonstrate novelty and non-obviousness over the original Astelin formulation, generic azelastine products, and related nasal antihistamine technology.

When did Astelin lose exclusivity?

Astelin lost practical U.S. market exclusivity after generic azelastine nasal sprays became available. The active ingredient is now a mature generic product.

Event	Approximate status
Original Astelin approval	FDA-approved in the 1990s
Original product exclusivity	Expired
Generic azelastine nasal spray	Commercially available
Current composition-of-matter protection	Expired
Current generic entry barrier	Primarily regulatory, manufacturing, and commercial
OTC azelastine market	Established through Astepro

The principal commercial distinction is now between prescription Astelin, generic azelastine, and OTC Astepro rather than between patented and unpatented versions of the same molecule.

What is the FDA and Orange Book status of Astelin?

Astelin is a small-molecule prescription nasal spray approved under an NDA. It is not a biologic and does not have a biosimilar pathway.

Generic azelastine nasal spray products are approved through abbreviated new drug applications. Because the reference product is an aqueous nasal spray, applicants must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements applicable to nasal products. The regulatory burden is higher than for a simple immediate-release oral solution because device performance and local delivery characteristics matter.

Is Astelin an OTC drug?

Astelin itself is associated with prescription use. Astepro, an azelastine hydrochloride nasal spray, was approved by FDA for over-the-counter use in the United States in 2021. The OTC product expanded consumer access to azelastine and changed the commercial market by placing a branded azelastine nasal spray beside prescription generics.[5]

This creates a two-tier market:

Segment	Principal products	Commercial basis
Prescription	Astelin and generic azelastine	Physician prescribing, formulary access, price
OTC	Astepro and related consumer products	Brand, shelf placement, advertising, convenience
Combination prescription	Dymista and generic equivalents where available	Dual mechanism and symptom coverage

What commercial opportunities exist for Astelin excipients?

1. Preservative-free azelastine nasal spray

The clearest excipient opportunity is removal of benzalkonium chloride. A preservative-free product could target:

• Chronic users
• Patients with nasal irritation
• Pediatric users
• Patients using several intranasal therapies
• Allergy sufferers seeking a better-tolerated product
• Clinicians concerned about repeated preservative exposure

The main technical challenge is multidose microbiological control. Commercial solutions include unit-dose packaging, one-way valve systems, filtered air systems, antimicrobial container technologies, and validated preservative-free multidose pumps.

A preservative-free claim would require comparative evidence on microbial robustness, local tolerability, spray performance, and stability. It would also need to justify any change in container closure or administration instructions.

2. Alternative viscosity systems

Hypromellose can be optimized or replaced with another mucoadhesive polymer. Candidate systems may include:

• Hydroxypropyl cellulose
• Carbomers
• Polyvinyl alcohol
• Polyethylene oxide
• Cellulose derivatives
• Chitosan-based systems

The objective would be increased nasal residence without clogging, excessive throat drainage, or deterioration in plume quality. A polymer platform could support differentiated claims around residence time, comfort, or reduced dosing frequency, although clinical benefit would need to be demonstrated.

3. Reduced-irritation excipient systems

A reformulated product could target lower nasal irritation through:

• Tighter pH control near physiological nasal conditions
• Improved osmolality
• Reduced preservative concentration
• Alternative preservation
• Lower surfactant burden
• Reduced deposition on sensitive mucosa
• Improved droplet-size distribution

The most commercially credible positioning would be tolerability and user adherence, not merely a different excipient list.

4. Device-excipient optimization

Pump engineering is a significant differentiation route. Opportunities include:

• Improved plume geometry
• Lower post-dose drip
• Consistent dose after storage
• Better performance at low fill volume
• Dose counters
• Lockable pumps
• Child-resistant packaging
• One-handed administration
• Better nasal deposition

A device change can create patentable subject matter and may support a differentiated 505(b)(2) or other regulatory strategy, depending on the degree of formulation and delivery change.

5. Unit-dose packaging

Unit-dose azelastine could eliminate the need for a chemical preservative. It could also improve portability and reduce contamination risk. The disadvantages are higher packaging cost, more material consumption, more waste, and potentially lower convenience for frequent users.

This strategy is more attractive for:

• Pediatric products
• Hospital or clinic use
• Travel products
• Premium allergy brands
• Patients using long-term therapy

6. Combination products

Azelastine can be combined with intranasal corticosteroids. Dymista combines azelastine hydrochloride and fluticasone propionate and provides a stronger commercial platform than single-agent azelastine because it addresses both histamine-mediated and inflammatory pathways.[6]

Excipient and device opportunities include:

• Improved suspension or solution stability
• Reduced settling in combination products
• Better dose uniformity
• Lower throat deposition
• Reduced pump clogging
• Preservative-free combination delivery
• Integrated dose counters
• Lower-volume or once-daily delivery

Combination products face more complex development, but they offer greater differentiation than an unmodified generic azelastine spray.

Which companies compete with Astelin?

The competitive field includes manufacturers of generic azelastine, branded OTC azelastine, combination nasal sprays, and alternative allergy therapies.

Competitor category	Representative products or companies	Competitive pressure
Generic azelastine	Multiple ANDA sponsors	Price erosion and formulary substitution
OTC azelastine	Astepro, Haleon/Viatris-related commercial channels	Consumer access and brand advertising
Combination spray	Dymista and generic equivalents	Broader symptom control
Intranasal corticosteroids	Flonase, Nasacort, Rhinocort and generics	Strong OTC presence
Oral antihistamines	Cetirizine, loratadine, fexofenadine	Convenience and consumer familiarity
Saline and barrier products	Multiple consumer-health companies	Low cost and low perceived risk

A company entering the azelastine market with the same excipient profile and an undifferentiated pump would face limited pricing power.

What generic entry risks exist for an Astelin-related product?

Generic competition is already established. The principal risks are commercial rather than patent-based.

Price erosion

A generic azelastine spray can compete on pharmacy substitution and formulary placement. A branded product must justify a premium through device usability, preservative-free status, OTC marketing, packaging, or demonstrated tolerability.

FDA product-quality scrutiny

Nasal sprays are sensitive to manufacturing variation. Key risk areas include:

• Delivered dose uniformity
• Spray content uniformity
• Droplet-size distribution
• Plume geometry
• Microbial limits
• Preservative efficacy
• Extractables and leachables
• Container closure integrity
• Pump actuation force
• Stability after opening

Formulation similarity

A generic applicant may use a different excipient system if it meets applicable regulatory requirements. A reformulator therefore cannot rely on the original Astelin excipient list as a barrier.

Substitution and channel risk

Prescription generic substitution can rapidly reduce brand volume. OTC competition creates a separate risk because consumers may select products based on price, shelf visibility, packaging, or advertising rather than prescriber preference.

What patent and licensing opportunities exist around azelastine excipients?

The strongest intellectual-property opportunities are likely to involve new delivery systems rather than the original Astelin formulation.

Potential patent claim areas

• Preservative-free multidose delivery
• Specific pump and container combinations
• Reduced-irritation formulations
• Bioadhesive polymer systems
• Controlled droplet-size nasal deposition
• Combination azelastine-corticosteroid formulations
• Improved stability under heat and humidity
• Unit-dose packaging
• Digital adherence or dose-counting systems

Licensing opportunities

Commercial licensing targets may include:

• Nasal-pump manufacturers with validated platforms
• Preservative-free multidose packaging suppliers
• Specialty pharmaceutical companies with allergy portfolios
• OTC consumer-health companies
• Generic manufacturers seeking differentiated products
• Contract development and manufacturing organizations with nasal-spray capacity

There is limited strategic value in licensing the basic Astelin excipient combination because it is old, widely understood, and not exclusive. Licensing becomes more attractive when linked to a protected device, a new preservative-free platform, a combination product, or a clinically validated tolerability advantage.

How strong is the Astelin patent estate?

The original Astelin patent estate is commercially weak because the active ingredient and basic nasal formulation are mature and genericized. A new entrant would need to build a separate patent estate around formulation, device, packaging, manufacturing, or clinical differentiation.

Patent layer	Current strategic strength
Azelastine composition of matter	Expired
Original Astelin formulation	Weak or expired
Basic excipient combination	Low protectability
Nasal pump engineering	Moderate, if technically specific
Preservative-free multidose system	Potentially strong
Combination product	Potentially strong, depending on claims and prior art
Manufacturing process	Moderate if process-specific and difficult to design around
Trade secrets	Potentially useful for process and device integration

Patent strength will depend on claim breadth, prior-art exposure, freedom to operate, and whether competitors can design around the claimed excipient concentrations or device parameters.

What is the outlook for Astelin-related revenue?

Astelin itself has limited ability to generate monopoly revenue. The highest-value commercial paths are:

1. Premium preservative-free azelastine.
2. OTC azelastine with strong consumer branding.
3. Azelastine-corticosteroid combination products.
4. Pediatric and chronic-use formulations.
5. Device licensing and contract manufacturing.
6. Regional products in markets where generic penetration remains lower.
7. Co-packaged allergy regimens combining antihistamine, corticosteroid, and saline products.

Revenue potential depends more on channel strategy than on the underlying molecule. Prescription generic sales are volume-driven and price-sensitive. OTC sales can support higher gross margins but require substantial investment in consumer marketing, retail distribution, and packaging.

What geographic markets offer opportunities?

The United States is highly competitive because of generic azelastine and OTC Astepro. Opportunities are more likely to arise from product differentiation than from simple geographic launch.

Potentially attractive markets include jurisdictions where:

• Azelastine nasal spray is approved but not widely available
• Preservative-free products have limited competition
• Local manufacturing reduces supply-chain cost
• Allergy prevalence supports intranasal therapy
• Regulatory pathways recognize established nasal products efficiently
• OTC switching is commercially feasible

Geographic expansion requires separate analysis of local trademarks, patent status, excipient permissions, device registration, pharmacopoeial requirements, and prescription-to-OTC rules. U.S. regulatory status does not establish freedom to operate in Europe, Japan, China, India, or other markets.

Key Takeaways

• Astelin is a 0.1% azelastine hydrochloride aqueous nasal spray delivering 137 micrograms per actuation.
• Its core excipients are benzalkonium chloride, edetate disodium, hypromellose, sodium citrate, sodium chloride, and purified water.
• The original active-ingredient and basic formulation protection has expired.
• Generic azelastine creates substantial price and substitution pressure.
• The most credible excipient opportunity is a preservative-free formulation with a validated multidose or unit-dose delivery system.
• Hypromellose and related polymers can support residence-time and tolerability differentiation, but viscosity must not compromise spray performance.
• Combination products, particularly azelastine plus an intranasal corticosteroid, offer stronger commercial differentiation.
• Astelin is not a biologic and has no biosimilar exposure. Its competitive risks are generic, OTC, formulation, and device risks.
• New patent value is more likely to reside in the pump, packaging, preservative-free system, combination formulation, or manufacturing process than in the original excipient list.
• A commercial launch based only on the legacy Astelin formulation would have limited pricing power.

FAQs

Can benzalkonium chloride be removed from an Astelin-type formulation?

Yes. Removal is technically feasible, but a multidose product would need an alternative microbiological-control strategy. Unit-dose packaging or a validated preservative-free multidose pump would be the principal approaches.

Would replacing hypromellose create a patentable azelastine formulation?

Potentially, but substitution alone is unlikely to be sufficient. A defensible patent would usually require a defined formulation, performance benefit, stability profile, deposition characteristic, or clinical tolerability advantage that is not obvious from prior art.

Can a new company launch generic azelastine without licensing Astelin?

Generally, yes, if it satisfies FDA abbreviated-application requirements and clears applicable patent and regulatory barriers. The original Astelin excipient combination is not a practical licensing requirement.

Is a preservative-free azelastine spray commercially superior to standard generic azelastine?

It can command differentiation if it demonstrates improved tolerability, adherence, or patient preference. It will usually face higher packaging and manufacturing costs and may require a premium commercial channel.

Does Dymista create a stronger opportunity than single-agent Astelin?

Usually. The azelastine-fluticasone combination addresses two therapeutic mechanisms and has greater formulation and device differentiation potential. It also faces more complex development, stability, regulatory, and intellectual-property requirements.

References

1. U.S. Food and Drug Administration. (2020). Astelin nasal spray prescribing information. Meda Pharmaceuticals Inc.

2. National Center for Biotechnology Information. (2024). Azelastine. PubChem compound summary. https://pubchem.ncbi.nlm.nih.gov

3. U.S. Food and Drug Administration. (2017). Nasal spray and inhalation solution products: Chemistry, manufacturing, and controls documentation. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (2021). FDA approves first over-the-counter nasal spray to treat seasonal allergies. https://www.fda.gov

6. U.S. Food and Drug Administration. (2023). Dymista prescribing information. Viatris Specialty LLC.